EnVision Summit
February 14-17, 2025
Register Now!
Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
March 9, 2025
Register Now!
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
CRU Eye Symposium
March 28-30, 2025
Register Now!
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Clearside Biomedical presents new data from CLS-AX ODYSSEY phase 2b trial
February 11th 2025The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib injectable suspension) in participants with neovascular age-related macular degeneration.
Shaffer-Hetherington-Hoskins Lecture at the 2025 Glaucoma 360 meeting
February 10th 2025M. Roy Wilson, presented the Shaffer-Hetherington-Hoskins Lecture at the Glaucoma 360 meeting held in San Francisco, California. This lecture was entitled, "Rethinking Race as a Risk Factor for Glaucoma: What Really Matters?"
DMEI resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
February 10th 2025Ooms' poster at the Association of University Professors of Ophthalmology annual meeting highlighted a study on gray area complications in strabismus surgery, showing that trainees are more likely than attendings to disclose these complications despite having similar baseline anxiety levels. Ooms is a PGY-4 ophthalmology resident at the Dean McGee Eye Institute.
4DMT announces positive 52-week data from phase 2b cohort of PRISM wet AMD study
February 10th 2025PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.
Glaucoma from the perspective of a veterinary ophthalmologist with Sara M. Thomasy, DVM, PhD, DACVO
February 9th 2025Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her research can align with human glaucoma research to move the entire field